会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • ESTERS AND CYCLIC DIESTERS OF 4-HYDROXY-1,3-BENZENEDIMETHANOL AND COMPOSITIONS AND METHODS EMPLOYING SUCH COMPOUNDS
    • 4-羟基-1,3-苯二甲酰胺及其组合物的酯和循环系统及其使用方法
    • WO1991019693A1
    • 1991-12-26
    • PCT/US1991003966
    • 1991-06-11
    • SCHERING CORPORATION
    • SCHERING CORPORATIONBLYTHIN, David, J.SHUE, Ho-JaneGANGULY, Ashit
    • C07C219/30
    • C07D491/04C07C217/46C07C217/70C07C219/30C07D321/00C07D495/04
    • Novel compounds selected from the group consisting of: (A) compounds of formula I(1), wherein: one of R and R represents the group (a) and the other represents hydrogen or R CO-; R represents C1 to C6-alkyl or the group -(CH2)n-Z-(CH2)m-Ar; Z represents O, S or -CH2-; n represents an integer of 1 to 8; m represents zero or an integer of 1 to 8; R is C1 to C10 alkyl, C3 to C8 cycloalkyl, aryl, heteroaryl, -N(R R ), or R O-; R , R , R , and R are each independently selected from hydrogen, C1 to C6 alkyl and Ar ; R and R are each independently C1-C8 alkyl; Ar and Ar are each independently selected from the group consisting of phenyl or substituted phenyl, (B) compounds of formula I(2), wherein: R represents C1 to C6-alkyl or the group -(CH2)n-Z-(CH2)m-Ar ; Ar is selected from the group consisting of phenyl, substituted phenyl, or phenyl optionally substituted by two adjacent groups which together form an additional benzenoid ring; ring Q represents one of the rings Q1, Q2, Q3 or Q4, and pharmaceutically acceptable acid addition salts thereof are described. These compounds possess favorable properties for the treatment of asthma and all types of chronic, obstructionary bronchopulmonary diseases.
    • 选自以下的新型化合物:(A)式I(1)化合物,其中:R 1和R 2之一表示(a)基团,另一个表示氢或R 7 CO - ; R 5表示C 1 -C 6烷基或基团 - (CH 2)n-Z-(CH 2)m -Ar; Z表示O,S或-CH 2 - ; n表示1〜8的整数, m表示0或1〜8的整数, R 7是C 1至C 10烷基,C 3至C 8环烷基,芳基,杂芳基,-N(R 9 R 10)或R 11 O-; R 3,R 4,R 9和R 10各自独立地选自氢,C 1至C 6烷基和Ar 1; R 6和R 11各自独立地为C 1 -C 8烷基; Ar和Ar 1各自独立地选自苯基或取代的苯基,(B)式I(2)的化合物,其中:R 5a表示C1至C6-烷基或基团 - (CH2) NZ-(CH 2)M-的Ar <2>; Ar 2选自苯基,取代的苯基或任选被两个相邻基团取代的苯基,它们一起形成另外的苯环; 环Q表示环Q1,Q2,Q3或Q4中的一个,并且其药学上可接受的酸加成盐被描述。 这些化合物具有治疗哮喘和所有类型的慢性阻塞性支气管肺疾病的有利性质。
    • 4. 发明申请
    • SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS
    • 作为神经营养因子拮抗剂的替代物,水合物和油脂
    • WO1996034857A1
    • 1996-11-07
    • PCT/US1996005659
    • 1996-05-01
    • SCHERING CORPORATION
    • SCHERING CORPORATIONREICHARD, Gregory, A.ASLANIAN, Robert, G.ALAIMO, Cheryl, L.KIRKUP, Michael, P.LUPO, AndrewMANGIARACINA, PietroMCCORMICK, Kevin, D.PIWINSKI, John, J.SHANKAR, BandarpalleSHIH, Neng-YangSPITLER, James, M.TING, Pauline, C.GANGULY, AshitCARRUTHERS, Nicholas, I.
    • C07D211/52
    • C07D295/185C07D211/52C07D211/58C07D211/76C07D295/13C07D333/22C07D401/04C07D401/06C07D409/06C07D413/12C07D413/14C07D417/12
    • Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or 3; b, d and e are independently 0, 1 or 2; R is H, C1-6 alkyl, -OH or C2-C6 hydroxyalkyl; A is an optionally substituted oxime, hydrazone or olefin; X is a bond, -C(O)-, -O-, -NR -, -S(O)e-, -N(R )C(O)-, -C(O)N(R )-, -OC(O)NR -, -OC(=S)NR -, -N(R )C(=S)O-, -C(=NOR )-, -S(O)2N(R )-, -N(R )S(O)2-, -N(R )C(O)O- or -OC(O)-; T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl; Q is -SR , -N(R )(R ), -OR , phenyl, naphthyl or heteroaryl; R , R , R , R , R and R are H, C1-6 alkyl, C2-C6 hydroxyalkyl, C1-C6 alkoxy-C1-C6 alkyl, phenyl or benzyl; or R and R , together with the nitrogen to which they are attached, form a ring; R is R or -OR ; Z is morpholinyl, optionally N-substituted piperazinyl, optionally substituted (a), or substituted (b); g is 0-3 and h is 1-4, provided the sum of h and g is 1-7; wherein aryl, heterocycloalkyl, heteroaryl, cycloalkyl and bridged cycloalkyl groups are optionally substituted; methods of treating asthma, cough, bronchospasm, inflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.
    • 由结构式(I)表示的化合物或其药学上可接受的盐,其中:a为0,1,2或3; b,d和e独立地为0,1或2; R为H,C 1-6烷基,-OH或C 2 -C 6羟烷基; A是任选取代的肟,腙或烯烃; X是键,-C(O) - , - O - , - NR 6 - , - S(O)e - , - N(R 6)C(O) N(R 6) - , - OC(O)NR 6 - , - OC(= S)NR 6 - , - N(R 6)C(= S) (= NOR 1) - , - S(O)2 N(R 6) - , - N(R 6)S(O)2 - , - N(R 6) O-或-OC(O) - ; T是H,苯二酰亚氨基,芳基,杂环烷基,杂芳基,环烷基或桥连环烷基; Q是-SR 6,-N(R 6)(R 7),-OR 6,苯基,萘基或杂芳基; R 6a,R 7a,R 8a,R 9a,R 6和R 7是H,C 1-6烷基,C 2 -C 6羟烷基,C 1 -C 6烷氧基-C 1 -C 6 烷基,苯基或苄基; 或R 6和R 7与它们所连接的氮一起形成环; R 9a是R 6或-OR 6; Z是吗啉基,任选取代的N-取代的哌嗪基,任选取代的(a)或取代的(b); g为0-3,h为1-4,h和g之和为1-7; 其中芳基,杂环烷基,杂芳基,环烷基和桥连环烷基任选被取代; 公开了用所述化合物治疗哮喘,咳嗽,支气管痉挛,炎性疾病和胃肠道疾病的方法,以及包含所述化合物的药物组合物。